Perricone R et al. - Intravenous immunoglobulin (IVIg) has a high response rate among SLE-recurrent spontaneous abortion (RSA) pregnant patients and may be considered safe and effective. Methods
Aim was to test the maternal and fetal outcome of SLE pts who suffered from RSA treated with IVIg alone during pregnancy
12 SLE-RSA pregnant pts were treated with high-dose IVIg and compared with 12 SLE-RSA pregnant pts treated with prednisolone and NSAIDs
They were evaluated for the clinical response before and during pregnancy, and before and after each treatment course
Pregnancy outcome in the two groups was also evaluated
Results
The groups characteristics were homogeneous at the beginning of pregnancy
A beneficial clinical response following IVIg treatment was noted in all pts
Antibodies and complement levels tended to normalize in most of the pts
These clinical and laboratory improvements were significant with respect to the control group
Pregnancy was successfully carried out in 100% SLE-RSA pts with a mean Apgar score of 8.92
See all
